131I-Caerin 1.1 and 131I-Caerin 1.9 for the treatment of non-small-cell lung cancer

Na Liu; Tiantian He; Zewei Xiao; Juan Du; Keke Zhu; Xiongying Liu; Tongsheng Chen; Wenjuan Liu; Guoying Ni; Xiaosong Liu; Tianfang Wang; Jiangtao Quan; Jinhe Zhang; Peipei Zhang; Jianwei Yuan

doi:10.3389/fonc.2022.861206

¹³¹I-Caerin 1.1 and ¹³¹I-Caerin 1.9 for the treatment of non-small-cell lung cancer

Front Oncol. 2022 Aug 15:12:861206. doi: 10.3389/fonc.2022.861206. eCollection 2022.

Authors

Na Liu¹, Tiantian He¹, Zewei Xiao¹, Juan Du¹, Keke Zhu¹, Xiongying Liu¹, Tongsheng Chen¹, Wenjuan Liu¹, Guoying Ni¹, Xiaosong Liu^{1

2}, Tianfang Wang^{1

3}, Jiangtao Quan⁴, Jinhe Zhang⁴, Peipei Zhang², Jianwei Yuan¹

Affiliations

¹ Department of Nuclear Medicine, The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
² Thoracic and Abdominal Radiotherapy Department, The First People's Hospital of Foshan, Foshan, China.
³ Genecology Research Centre, University of the Sunshine Coast, Sunshine Coast, QLD, Australia.
⁴ Department of Nuclear Medicine, General Hospital of the Southern Theatre Command, People's Liberation Army of China, Guangzhou, China.

Abstract

Objective: To investigate the effect of the ¹³¹I-labeled high-affinity peptides Caerin 1.1 and Caerin 1.9 for the treatment of A549 human NSCLC cells.

Methods: ① 3-[4,5-Dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and plate clone formation assays were performed to confirm the in vitro anti-tumor activity of Caerin 1.1 and Caerin 1.9. ② Chloramine-T was used to label Caerin 1.1 and Caerin 1.9 with ¹³¹I, and the Cell Counting Kit 8 assay was performed to analyze the inhibitory effect of unlabeled Caerin 1.1, unlabeled Caerin 1.9, ¹³¹I-labeled Caerin 1.1, and ¹³¹I-labeled Caerin 1.9 on the proliferation of NSCLC cells. An A549 NSCLC nude mouse model was established to investigate the in vivo anti-tumor activity of unlabeled Caerin 1.1, unlabeled Caerin 1.9, ¹³¹I-labeled Caerin 1.1, and ¹³¹I-labeled Caerin 1.9.

Results: ① Caerin 1.1 and Caerin 1.9 inhibited the proliferation of NSCLC cells in vitro in a concentration-dependent manner. The half-maximal inhibitory concentration was 16.26 µg/ml and 17.46 µg/ml, respectively, with no significant intergroup difference (P>0.05). ② ¹³¹I-labeled Caerin 1.1 and ¹³¹I-labeled Caerin 1.9 were equally effective and were superior to their unlabeled versions in their ability to inhibit the proliferation and growth of NSCLC cells (P>0.05).

Conclusions: ¹³¹I-labeled Caerin 1.1 and ¹³¹I-labeled Caerin 1.9 inhibit the proliferation and growth of NSCLC cells and may become potential treatments for NSCLC.

Keywords: 131I labeling; A549 cells; Caerin peptide; high-affinity peptides; non-small-cell lung cancer.